[1] 赵丽媛. 冠心病住院患者二级预防用药现状调查—附1 150例分析[D].大连:大连医科大学,2017:7-8.
[2] 刘明波,李镒冲,刘世炜,等.2010年中国人群高血压疾病负担[J].中华流行病学杂志,2014,35(6):680-683.
[3] 中华医学会心血管病分会介入心脏病学组、中国医师协会心血管内科医师分会、血栓防治专业委员会和中华心血管病杂志编辑委员会.稳定性冠心病诊断和治疗指南[J].中华心血管病杂志,2018,46(9):680-694.
[4] 潘秋香,谢艳萍,陈柳香.Morisky问卷调查癌痛病人口服药物依从性的信度和效度[J].全科护理,2019,17(19):2397-2398.
[5] 陈强,曲珊珊,黄欣.中文版MMAS-8 评价心血管慢病患者用药依从性的信效度分析与实践[J].中国药房,2019,30(2):268-271.
[6] Schiele F,Ecarnot F,Chopard R.Coronary artery disease:Risk stratification and patient selection for more aggressive secondary prevention[J].Eur J Prev Cardiol,2017,24(3_suppl):88-100.
[7] Kumar S,deLusignan S,Mcgovern A,et al.Ischaemic stroke,haemorrhage,and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation:A population based study from UK primary care[J].BMJ,2018,360:k342.
[8] Ibanez B,James S,Agewall S,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart J,2018,39(2):119-177.
[9] Nalini M,Sepanlou S,Pourshams A,et al.Drug use for secondary prevention of cardiovascular diseases in Golestan,Iran:Results from the Golestan cohort study[J].Arch Iran Med,2018,21(3):86-94.
[10 Benjamin EJ,Virani SS,Callaway CW,et al.Heart diseaseand stroke statistics-2018 Update:A report from the American heart association[J].Circulation,2018,137(12):e67-e492.
[11] 周艺,贾立敏,霍奇文,等.冠心病病人二级预防服药依从性预测模型的构建[J].护理研究,2022,36(11):1925-1930.
[12] 卫攀,郭晓岚,尹姣,等.冠心病患者疾病感知和用药依从性的调查研究[J].上海护理,2021,21(5):46-48.
[13] 许永祖,段彩荣.老年冠心病二级预防用药的依从性及干预措施探讨[J].临床研究,2019,27(10):33-35.
[14] 金淳淳,吕蒙.再发急性冠脉综合征患者冠心病二级预防服药依从性调查[J]. 中国卫生工程学,2020,19(4):523-524.
[15] 邓斌,高日扬.1 682例老年冠心病患者出院后药物医嘱依从性调查及影响因素分析[J].中国医院用药评价与分析,2019,19(8):997-999,1004. |
